Forward P/E is 13 and PEG is about 1.2 (relatively low for a solid growth stock) Buy, Buy, Buy
Lot of billionaires like this stock. I couldn't figure out why but I guess they are looking ahead not behind. Guess I'll try to do the same. I've advanced as an investor and do not listen to "analyst noise" of which you will hear a lot today.
The bottom for Micron is already in. Greece will strike a deal and the whole world will be great again. Sarcasm added.
You know it's going to happen. I said on many message boards that ACA subsidies would be upheld on a 6-3 vote. The Supreme Court made the right decision in my opinion. you do not scrap a whole bill over a technical error. Bills have errors all the time...there are very few clean bills. Positive news on Greece tomorrow and the market skyrockets at least for a day or two.
LOL. Where's the rest of the article. It's called loss leading. You draw people into the store by selling things like eggs at a loss to draw customers into store. Note I said at a loss to the store. Cal-Maine is still kicking it!
Not me. BX is still 10-20% below it's market value. t's about to break out and head to the 48-49 area. I've been in BX for years, just hold it and you can make some serious coin. BTW I have an opposite view from Sam in that I think the market is undervalued with the exception of some biotechs, AMZN, NFLX, TESL, CYBR, FEYE etc.
No rate increase this year and probably well into next. This economy is a rare bird, but so far it's the weakest recovery on record. TMV is banking on a strong recovery and higher rates. I'm not sure that is going to play out. Remember, the "experts" have been saying this for 5 years.
Agree in part, but disagree on the dividend. Dividend can be an important part of total return for mature companies. In my opinion, GILD is still a GROWTH company and I would rather see the money that will be paid out in dividends used for growth and acquisition. GILD's focus should be on strategic acquisitions-not sure about VRTX-but I think ICPT or ACAD (with potential $4B drug) fit nicely. ACAD seems slightly undervalued while ICPT seems slightly overvalued, but a purchase of either at a reasonable price would make good sense and I think the stock would move accordingly.
Only those without a clue (and there are many) would sell on this news. I'm sure CNBC (clueless) and Bloomberg (anti-Gilead) will pump this story. But, in reality the Merck results just crystalizes the fact that Gilead is #1 in HCV and will stay that way for a long time.